HUP9903673A3 - Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc - Google Patents

Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc

Info

Publication number
HUP9903673A3
HUP9903673A3 HU9903673A HUP9903673A HUP9903673A3 HU P9903673 A3 HUP9903673 A3 HU P9903673A3 HU 9903673 A HU9903673 A HU 9903673A HU P9903673 A HUP9903673 A HU P9903673A HU P9903673 A3 HUP9903673 A3 HU P9903673A3
Authority
HU
Hungary
Prior art keywords
azt
hiv
alone
treatment
combination
Prior art date
Application number
HU9903673A
Other languages
English (en)
Original Assignee
Vertex Pharmaceuticals Inc Cam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc Cam filed Critical Vertex Pharmaceuticals Inc Cam
Publication of HUP9903673A2 publication Critical patent/HUP9903673A2/hu
Publication of HUP9903673A3 publication Critical patent/HUP9903673A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HU9903673A 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc HUP9903673A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (2)

Publication Number Publication Date
HUP9903673A2 HUP9903673A2 (hu) 2000-03-28
HUP9903673A3 true HUP9903673A3 (en) 2000-08-28

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903673A HUP9903673A3 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc

Country Status (23)

Country Link
US (1) US5646180A (hu)
EP (1) EP0866696B1 (hu)
JP (1) JP2000501713A (hu)
KR (1) KR19990071750A (hu)
CN (1) CN1203530A (hu)
AP (1) AP864A (hu)
AT (1) ATE279922T1 (hu)
AU (1) AU722850B2 (hu)
BR (1) BR9611861A (hu)
CA (1) CA2238471A1 (hu)
CZ (1) CZ291994B6 (hu)
DE (1) DE69633680T2 (hu)
ES (1) ES2231828T3 (hu)
HU (1) HUP9903673A3 (hu)
NO (1) NO317837B1 (hu)
NZ (1) NZ324603A (hu)
OA (1) OA10691A (hu)
PL (1) PL187747B1 (hu)
PT (1) PT866696E (hu)
RU (1) RU2203658C2 (hu)
UA (1) UA61902C2 (hu)
WO (1) WO1997020554A1 (hu)
ZA (1) ZA9610139B (hu)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6486136B1 (en) * 1996-06-25 2002-11-26 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
AP9801419A0 (en) * 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
DK1328213T3 (da) * 2000-10-16 2005-11-28 Conor Medsystems Inc Ekspanderbar medicinsk indretning til afgivelse af et nyttigt middel
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
CA2634932A1 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
US8642642B2 (en) * 2006-04-19 2014-02-04 Abbott Laboratories Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3110381B1 (en) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
MX2020012801A (es) 2018-05-28 2021-03-25 Attends Healthcare Products Inc Laminado con capa de sequedad para articulos absorbentes.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
CA2238471A1 (en) 1997-06-12
AU1148697A (en) 1997-06-27
BR9611861A (pt) 1999-05-18
NO982556D0 (no) 1998-06-04
NO317837B1 (no) 2004-12-20
NZ324603A (en) 2000-08-25
NO982556L (no) 1998-06-04
ES2231828T3 (es) 2005-05-16
AP864A (en) 2000-08-11
KR19990071750A (ko) 1999-09-27
US5646180A (en) 1997-07-08
EP0866696A1 (en) 1998-09-30
JP2000501713A (ja) 2000-02-15
ATE279922T1 (de) 2004-11-15
CZ170898A3 (cs) 1998-09-16
HUP9903673A2 (hu) 2000-03-28
OA10691A (en) 2001-05-04
WO1997020554A1 (en) 1997-06-12
CZ291994B6 (cs) 2003-07-16
PL187747B1 (pl) 2004-09-30
DE69633680T2 (de) 2006-02-23
DE69633680D1 (de) 2004-11-25
AU722850B2 (en) 2000-08-10
AP9801340A0 (en) 1998-09-30
PT866696E (pt) 2005-03-31
UA61902C2 (en) 2003-12-15
EP0866696B1 (en) 2004-10-20
ZA9610139B (en) 1997-06-17
PL327061A1 (en) 1998-11-23
RU2203658C2 (ru) 2003-05-10
CN1203530A (zh) 1998-12-30

Similar Documents

Publication Publication Date Title
HUP9903673A3 (en) Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc
PL323934A1 (en) Absorptive article, such as napkin or the like
EP0678723A4 (en) NIZOV CROSSBOW.
GR3031226T3 (en) Body conforming absorbent article.
AU6924796A (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
ZA944890B (en) Doubled haploids
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
AU2418499A (en) Org-5222 in the treatment of depression
HK1004659A1 (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
FI933907A0 (fi) Refraktometri
EP0671500A3 (en) Compositions for the treatment of textiles.
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
EP1032266A4 (en) USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS
AU2325695A (en) The wave rider body suit
EP0684004A3 (de) Sanitärgegenstand.
GB9415921D0 (en) Infra-red body
NO307542B1 (no) Kasseformet legeme, særlig postkasse, samt front til samme
FR2697913B3 (fr) Microéprouvette comportant des organes accroissant la surface.
DE29620351U1 (de) Am Körper tragbarer Schmuckrahmen
PL304504A1 (en) Desktop or the like
AUPM650494A0 (en) The wave rider body suit
AU657882B2 (en) Improvements in or relating to the treatment of diarrhoea
GB9506149D0 (en) The body people
AUPN000894A0 (en) The bath
CA65516S (en) Snowmobile suit or the like

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees